MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Начало・Списък с акции・Novartis AG

Novartis AG

Затворен

112.41 1.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

110.38

Максимум

114.32

Ключови измерители
By Trading Economics
Приходи	-369M 2.8B
Продажби	386M 14B
P/E Средно за сектора	18.992 63.778
EPS	1.98
Дивидентна доходност	3.47
Марж на печалбата	20.8
Служители	75,883
EBITDA	-426M 5.2B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+0.21% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.47% 2.39%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6.9B 221B
Предишно отваряне	110.96
Предишно затваряне	112.41

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

109.97 / 112.06 Подкрепа & съпротива

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2025 г., 06:57 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31.01.2025 г., 09:49 ч. UTC

Печалби

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31.01.2025 г., 08:06 ч. UTC

Печалби

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31.01.2025 г., 06:32 ч. UTC

Печалби

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17.03.2025 г., 07:34 ч. UTC

Пазарно говорене

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4.03.2025 г., 18:45 ч. UTC

Печалби

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11.02.2025 г., 09:25 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11.02.2025 г., 06:42 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11.02.2025 г., 06:22 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11.02.2025 г., 06:20 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11.02.2025 г., 06:19 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11.02.2025 г., 06:18 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Is Expected to Close in 1H of 2025

11.02.2025 г., 06:18 ч. UTC

Придобивния, сливания и поглъщания

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11.02.2025 г., 06:17 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11.02.2025 г., 06:16 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Anthos Therapeutics for $925M Upfront

11.02.2025 г., 06:15 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Anthos Therapeutics

4.02.2025 г., 15:16 ч. UTC

Топ новини

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4.02.2025 г., 08:12 ч. UTC

Пазарно говорене

Печалби

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31.01.2025 г., 13:56 ч. UTC

Печалби

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31.01.2025 г., 09:59 ч. UTC

Горещи акции

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31.01.2025 г., 07:50 ч. UTC

Пазарно говорене

Novartis's Outlook Exceeds Market Views -- Market Talk

31.01.2025 г., 07:46 ч. UTC

Пазарно говорене

Печалби

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31.01.2025 г., 06:03 ч. UTC

Печалби

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis Issues 2025 View

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis 4Q Oper Pft $3.53B

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis 4Q Net Pft $2.82B

31.01.2025 г., 06:02 ч. UTC

Печалби

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31.01.2025 г., 06:02 ч. UTC

Печалби

Novartis 4Q Core Operating Profit $4.86B

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

0.21% нагоре

12-месечна прогноза

Среден 111 USD 0.21%

Висок 125 USD

Нисък 97 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Novartis AG през последните 3 месеца.

Техническа оценка

By Trading Central

109.97 / 112.06Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.